NasdaqCM:DFFN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Diffusion Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DFFN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.0%

DFFN

0.4%

US Biotechs

1.3%

US Market


1 Year Return

-55.7%

DFFN

37.9%

US Biotechs

15.8%

US Market

Return vs Industry: DFFN underperformed the US Biotechs industry which returned 35.6% over the past year.

Return vs Market: DFFN underperformed the US Market which returned 13.8% over the past year.


Shareholder returns

DFFNIndustryMarket
7 Day-1.0%0.4%1.3%
30 Day-17.2%0.4%-4.1%
90 Day-16.0%-3.6%8.4%
1 Year-55.7%-55.7%40.4%37.9%18.4%15.8%
3 Year-96.8%-96.8%14.4%8.9%38.2%29.0%
5 Yearn/a22.8%14.1%84.9%64.0%

Price Volatility Vs. Market

How volatile is Diffusion Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Diffusion Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

1.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DFFN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DFFN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DFFN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: DFFN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DFFN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DFFN is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Diffusion Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

29.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DFFN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DFFN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DFFN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if DFFN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if DFFN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DFFN's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Diffusion Pharmaceuticals performed over the past 5 years?

-1.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DFFN is currently unprofitable.

Growing Profit Margin: DFFN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DFFN is unprofitable, and losses have increased over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare DFFN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DFFN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: DFFN has a negative Return on Equity (-37.23%), as it is currently unprofitable.


Next Steps

Financial Health

How is Diffusion Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: DFFN's short term assets ($26.7M) exceed its short term liabilities ($1.8M).

Long Term Liabilities: DFFN's short term assets ($26.7M) exceed its long term liabilities ($1.3M).


Debt to Equity History and Analysis

Debt Level: DFFN is debt free.

Reducing Debt: DFFN currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DFFN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DFFN has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 8% each year.


Next Steps

Dividend

What is Diffusion Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DFFN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DFFN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DFFN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DFFN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DFFN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Bob Cobuzzi (55 yo)

no data

Tenure

Dr. Robert J. Cobuzzi, Jr., also known as Bob, Ph.D., serves as a Independent Director at Diffusion Pharmaceuticals Inc. since January 10, 2020 and serves as its President & Chief Executive Officer since S ...


Leadership Team

NamePositionTenureCompensationOwnership
David Kalergis
Co-Founder & Chairman of the Board4.67yrsUS$475.72k0.012%
$ 6.3k
John Gainer
Co-Founder4.67yrsUS$403.78k0.049%
$ 26.1k
William Hornung
Chief Financial Officer2yrsUS$355.13k0.034%
$ 18.2k
Robert Cobuzzi
Presidentno datano data0.062%
$ 32.8k
William Elder
General Counsel & Corporate Secretaryno datano datano data
David Jones
Senior Medical Advisor8yrsno datano data
Kelly Hoy
Director of Project Managementno datano datano data
Harry Cook
Vice President of Clinical Operations4yrsno datano data
Douglas Gravatt
Senior Consultant for Manufacturingno datano datano data
Brian Bollwage
Senior Consultant - Regulatory Affairsno datano datano data

6.0yrs

Average Tenure

57yo

Average Age

Experienced Management: DFFN's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Kalergis
Co-Founder & Chairman of the Board4.67yrsUS$475.72k0.012%
$ 6.3k
John Gainer
Co-Founder4.67yrsUS$403.78k0.049%
$ 26.1k
Robert Cobuzzi
Presidentno datano data0.062%
$ 32.8k
Alan Levin
Independent Director4.67yrsUS$77.70k0.0026%
$ 1.4k
Mark Giles
Lead Independent Directorno dataUS$77.20k0.084%
$ 44.7k
Jeffrey Saver
Member of Scientific Advisory Board4yrsno datano data
Robert Adams
Independent Director4.67yrsUS$75.93k0.0056%
$ 3.0k
Gene Barnett
Member of Scientific Advisory Board4yrsno datano data
William Hiatt
Member of Scientific Advisory Board4yrsno datano data
Guy Chisolm
Chairman of Scientific Advisory Board4yrsno datano data
Connie Hess
Member of Scientific Advisory Board4yrsno datano data
Karen Johnston
Member of Scientific Advisory Board4yrsno datano data

4.0yrs

Average Tenure

67.5yo

Average Age

Experienced Board: DFFN's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1263.6%.


Top Shareholders

Company Information

Diffusion Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diffusion Pharmaceuticals Inc.
  • Ticker: DFFN
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$53.119m
  • Shares outstanding: 64.00m
  • Website: https://www.diffusionpharma.com

Number of Employees


Location

  • Diffusion Pharmaceuticals Inc.
  • 1317 Carlton Avenue
  • Suite 200
  • Charlottesville
  • Virginia
  • 22902
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DFFNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 2008
DP81BST (Boerse-Stuttgart)YesCommon StockDEEURMar 2008
DP81DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2008

Biography

Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 23:56
End of Day Share Price2020/09/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.